Merus N.V. announced on February 5, 2025, that the New England Journal of Medicine (NEJM) published results from the registrational Phase 2 eNRGy trial for Bizengri® (zenocutuzumab). Bizengri® is indicated for adults with advanced, unresectable, or metastatic pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) harboring an NRG1 gene fusion.
The publication reviews data from 204 patients across 12 tumor types, concluding that zenocutuzumab demonstrated durable efficacy in patients with advanced NRG1+ cancer, particularly NSCLC and pancreatic adenocarcinoma, with a favorable safety profile. This marks the first reported prospective clinical trial targeting cancers with this rare genomic alteration.
This peer-reviewed publication in a highly respected medical journal provides significant scientific validation for Bizengri's clinical benefits. It reinforces the drug's recent FDA accelerated approval and highlights its importance as a targeted treatment option for patients with limited alternatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.